PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Expression and Distribution of Galectin-3 in Chromophobe and Papillary Carcinomas.

Abstract Probably due to their low occurrence, chromophobe and papillary renal cell carcinomas are less well characterized and, currently, there are no reliable prognostic markers for this group of patients. Moreover, the optimal therapy for patients with non-clear renal cell carcinoma (RCC) is unknown yet. Although elevated levels of Galectin-3 (Gal-3) were associated with poor prognosis in conventional RCC, the impact of this protein on carcinogenesis of chromophobe and papillary entities has not been previously described.
PMID
Related Publications

Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers.

A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.

Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.

Expression of CD9/motility-related protein 1 (MRP-1) in renal parenchymal neoplasms: consistent expression in papillary and chromophobe renal cell carcinomas.

RET protein expression in papillary renal cell carcinoma.

Authors

Mayor MeshTerms
Keywords

Galectin-3

chromophobe

immunohistochemistry

renal cell carcinoma

Journal Title anticancer research
Publication Year Start




PMID- 29277781
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Expression and Distribution of Galectin-3 in Chromophobe and Papillary
      Carcinomas.
PG  - 259-263
AB  - BACKGROUND/AIM: Probably due to their low occurrence, chromophobe and papillary
      renal cell carcinomas are less well characterized and, currently, there are no
      reliable prognostic markers for this group of patients. Moreover, the optimal
      therapy for patients with non-clear renal cell carcinoma (RCC) is unknown yet.
      Although elevated levels of Galectin-3 (Gal-3) were associated with poor
      prognosis in conventional RCC, the impact of this protein on carcinogenesis of
      chromophobe and papillary entities has not been previously described. MATERIALS
      AND METHODS: Gal-3 expression was investigated in 34 consecutive cases of RCCs,
      including 19 papillary carcinomas and 15 chromophobe carcinomas. RESULTS:
      Immunohistochemical analysis of Gal-3 in tumor cells showed 3 patterns of
      expression: membranous, cytoplasmic and nuclear staining. Most tumors included in
      our study showed a cytoplasmic expression and it was almost equally distributed
      between the histologic subtypes. However, only nuclear staining of Gal-3 was
      associated with both Fuhrman grade and tumor stage (p=0.016 and p=0.032,
      respectively) in chromophobe subtype. CONCLUSION: Our results indicate that the
      nuclear expression of Gal-3 has an essential role in the development of
      chromophobe carcinoma. The association with advanced tumor stage and nuclear
      grade suggests that this protein is an indicator of aggressiveness in the
      chromophobe subtype, thus targeting anti-nuclear transport may prove an effective
      therapy for this particular group of patients.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Cioca, Andreea
AU  - Cioca A
AD  - Department of Histology, Angiogenesis Research Center, "Victor Babes" University 
      of Medicine and Pharmacy, Timisoara, Romania [email protected]
FAU - Muntean, Diana
AU  - Muntean D
AD  - Department of Pathology, Regional Hospital, Cluj-Napoca, Romania.
FAU - Bungardean, Catalina
AU  - Bungardean C
AD  - Department of Pathology, Regional Hospital, Cluj-Napoca, Romania.
FAU - Raica, Marius
AU  - Raica M
AD  - Department of Histology, Angiogenesis Research Center, "Victor Babes" University 
      of Medicine and Pharmacy, Timisoara, Romania.
FAU - Cimpean, Anca Maria
AU  - Cimpean AM
AD  - Department of Histology, Angiogenesis Research Center, "Victor Babes" University 
      of Medicine and Pharmacy, Timisoara, Romania.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Galectin 3)
RN  - 0 (galectin-3, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Papillary/*metabolism/pathology
MH  - Carcinoma, Renal Cell/*metabolism/pathology
MH  - Female
MH  - Galectin 3/*metabolism
MH  - Humans
MH  - Kidney Neoplasms/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
OTO - NOTNLM
OT  - *Galectin-3
OT  - *chromophobe
OT  - *immunohistochemistry
OT  - *renal cell carcinoma
EDAT- 2017/12/27 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/11 00:00 [received]
PHST- 2017/11/01 00:00 [revised]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 38/1/259 [pii]
AID - 10.21873/anticanres.12216 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):259-263. doi: 10.21873/anticanres.12216.